Overview

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Status:
Completed
Trial end date:
2019-10-24
Target enrollment:
Participant gender:
Summary
This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
ADC Therapeutics S.A.
ADC Therapeutics SARL